September 19th 2024
"But for physicians considering chemotherapy for which there is equipoise, the Decipher test could be used to swing the decision one way or the other," says Gerhardt Attard, MD, PhD, FRCP.
September 16th 2024
Sipuleucel-T: An innovative immunotherapy option for metastatic castration-resistant prostate cancer
May 19th 2022In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Kelvin A. Moses, MD, PhD, discusses the prostate cancer immunotherapy treatment sipuleucel-T (Provenge).
Urology Times 50 Innovations Series: Anatomic radical prostatectomy
May 11th 2022"Anatomic radical prostatectomy really transformed radical prostatectomy from a very morbid operation with high risk, performed rarely, to one that became a commonly utilized treatment for prostate cancer," says Christopher L. Amling, MD, FACS.
“Shooting for the Moon” means reducing metastatic prostate cancer diagnoses
May 4th 2022“We have an incredible opportunity to save countless more lives with better screening practices and renewed recommendations, which accurately reflect the realities we as independent physicians see within our patient populations every day,” Jonathan Henderson, MD, writes in this letter to the editor.
Abiraterone-based triplet boosts survival in de novo mCSPC
May 2nd 2022Findings from the PEACE-1 trial published in the Lancet showed that adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved overall survival in patients with de novo metastatic castration-sensitive prostate cancer.
Final survival analysis shows significant boost with enzalutamide in mHSPC
May 2nd 2022The final results from the phase 3 ARCHES trial showed that the addition of enzalutamide to androgen deprivation therapy also continued to improve radiologic progression-free survival and other secondary end points.
RP appears more effective against high-risk prostate cancer
April 28th 2022"It’s very possible that the PSA screening-detected high-risk prostate cancer portends a more favorable outlook when compared with the pre-PSA era, regardless of the type of primary therapy utilized," writes Badar M. Mian, MD.